In this population-based Swedish register study evaluating real-world outcomes of first-line PD-(L)1 inhibitor treatment in advanced/metastatic NSCLC, we included more patients and had a longer follow-up compared to our previous investigation [5], allowing for conclusive survival analyses in the overall study populations defined by histology, and descriptive subgroup analyses by ECOG PS and PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.